You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • SAT0159 Results of A Phase 1b Study of The Safety, Tolerability, and Pharmacokinetics of The MMP9 Inhibitor GS-5745 in Patients with Rheumatoid Arthritis (RA)

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - other biologic treatment
SAT0159 Results of A Phase 1b Study of The Safety, Tolerability, and Pharmacokinetics of The MMP9 Inhibitor GS-5745 in Patients with Rheumatoid Arthritis (RA)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gossage D, Cieslarova B, Ap S, et al
SAT0159 Results of A Phase 1b Study of The Safety, Tolerability, and Pharmacokinetics of The MMP9 Inhibitor GS-5745 in Patients with Rheumatoid Arthritis (RA)
Annals of the Rheumatic Diseases 2016;75:723-724.